{"id":"W3042095160","doi":"10.1136/jitc-2020-000891","title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Bristol-Myers Squibb; Ono Pharmaceutical; National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; University of Texas MD Anderson Cancer Center","keywords":"Nivolumab; Medicine; Sunitinib; Ipilimumab; Renal cell carcinoma; Internal medicine; Randomized controlled trial; Oncology; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001693459,0.0003654546,0.002366127,0.0001989843,0.00007730006,0.00002481262,0.0001571956,0.0001229104,0.00007246981],"category_scores_gemma":[0.000200357,0.0002295427,0.0005433786,0.0001932589,0.0002388305,0.0001508588,0.0000266036,0.0004844054,1.597163e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004496229,"about_ca_system_score_gemma":0.001463207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001382806,"about_ca_topic_score_gemma":0.00009467603,"domain_scores_codex":[0.9961106,0.0006643534,0.00155824,0.0003654813,0.0009611414,0.0003402168],"domain_scores_gemma":[0.9963655,0.001266854,0.001308708,0.0002844514,0.0005308514,0.0002436158],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9422849,0.00138875,0.04677108,0.00008493234,0.001353931,0.00004721269,0.0008391219,0.00007328096,0.0009991027,0.000004025902,0.00001726354,0.006136346],"study_design_scores_gemma":[0.8249253,0.05101782,0.1209302,0.000166811,0.0006823579,0.000003937325,0.0003408389,0.00008956106,0.001486466,0.000004007928,0.0001564346,0.0001962634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934313,0.001521176,0.0002766148,0.0004680229,0.0006460003,0.003502117,0.00007404187,0.000009257091,0.00007142164],"genre_scores_gemma":[0.9973435,0.0003557891,0.001687081,0.00008554057,0.0001056426,0.0001773615,0.00002132571,0.00006477988,0.0001589491],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1173597,"threshold_uncertainty_score":0.936048,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04926157250532811,"score_gpt":0.3799343260798284,"score_spread":0.3306727535745003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}